Catalyst Event
Alteogen Inc (196170) · Other
From KRX Bio Technology Transfer Index (KBIOTT)
3/16/2026, 12:00:00 AM
Alteogen signed a CMO agreement with EstigenBio on 2026-03-16 for the commercial production of its Eylea biosimilar. This is expected to have a medium impact as it signals the transition to commercial supply, expected.
Korean Translation
2026년 3월 16일 아일리아 바이오시밀러 상업 생산을 위한 CMO 계약을 체결함. 상업화 단계 진입에 따른 실적 가시화로 중간 수준의 영향력이 예상됨.
Related Recent Events
D&D Pharmatech Inc (347850) · Other
Top-line results from the Phase 2 clinical trial of MASH treatment candidate DD01, including 48-week liver biopsy data, are scheduled to be announced around May 2026. High importance is estimated due to the potential for significant price impact (≥10%) upon the release of Phase 2 clinical trial results scheduled
5/31/2026, 12:00:00 AM
SK Biopharmaceuticals Co Ltd (326030) · Other
The 14th Annual General Meeting of Shareholders is scheduled.
3/26/2026, 12:00:00 AM
Yuhan Corp (000100) · Other
The 103rd Annual General Meeting to approve FY2025 financial statements and a cash dividend of KRW 600 per common share on March 20, 2026, with minimal market impact anticipated, is scheduled.
3/20/2026, 12:00:00 AM
LigaChem Biosciences Inc (141080) · Other
Presentation of preclinical results for two next-generation BCMA-targeting ADC candidates at the AACR Annual Meeting scheduled. Expected impact is Medium as major conference presentations typically influence biotech valuations.
3/18/2026, 12:00:00 AM
Daewoong Pharmaceutical Co Ltd (069620) · Other
In its 2025 annual report filed on March 18, 2026, the company removed its '1 Product, 1 Trillion KRW Sales' slogan, shifting its strategic focus to fostering multiple global blockbuster drugs; low market impact from strategic shift is expected.
3/18/2026, 12:00:00 AM
Hanmi Pharm Co Ltd (128940) · Other
Announced a shareholder return plan on March 16, 2026, to be proposed at the March 31 AGM, including the cancellation of 85,316 treasury shares and a record-high cash dividend; expected to cause a >10% price impact due to significant shareholder value enhancement expected.
3/16/2026, 12:00:00 AM